Early biological follow-up revealed transaminase increases in all patients [ASAT from a mean of 42.5 IU at M0 to 74.6 IU at M2 (range 26–210) and ALAT from a mean of 29.3 IU at M0 to 69.8 IU at M2 (range 17–311 UI)] without hepatic failure, followed by complete normalization at M3 for 24/27 patients. This evidence concerns the gene ABCB7 and liver failure.